首页> 外文期刊>日本神经精神药理学会志 >Predicting Dopamine D2 Receptor Occupancy Following Antipsychotic Dose Reduction: A Pilot PET Study
【24h】

Predicting Dopamine D2 Receptor Occupancy Following Antipsychotic Dose Reduction: A Pilot PET Study

机译:预测抗精神病药剂量减少后的多巴胺D2受体占用:飞行员宠物研究

获取原文
获取原文并翻译 | 示例
           

摘要

Position emission tomography (PET) studies have demonstrated that a therapeutic window of striatal dopamine D2 receptor occupancy (65-80%) is associated with clinical response for most antipsychotic drugs in younger adults (Farde et al,1995; Kapur et al,2000). This observation has been used to predict the therapeutic dose range of new drugs and has contributed to cuixent recommended antipsychotic dose range. However, unfortunately, measuring dopamine D2 occupancy levels with brain imaging techniques such as PET is not feasible for clinical purposes due to lack of wide availability and its high cost. Therefore, dose adjustment has always been associated with difficulties and currently been performed, relying on a trial-and-error strategy that carries a risk of relapse and adverse effects (Uclnda et al, 2009).
机译:位置排放断层扫描(PET)研究表明,纹状体多巴胺D2受体占用率的治疗窗(65-80%)与较年轻成人的大多数抗精神病药物的临床反应有关(Farde等,1995; Kapur等,2000) 。 该观察结果已被用于预测治疗剂量范围的新药,并有助于Cuxent推荐的抗精神剂量范围。 然而,遗憾的是,由于缺乏可用性和高成本,测量诸如PET的脑成像技术(例如PET)的多巴胺D2占用水平对临床目的不可行。 因此,剂量调整始终与困难有关,目前已经进行,依赖于携带复发和不利影响风险的试验和错误策略(UCLNDA等,2009)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号